176 related articles for article (PubMed ID: 35952320)
1. Association of
Hino K; Nishina T; Kajiwara T; Bando H; Nakamura M; Kadowaki S; Minashi K; Yuki S; Ohta T; Hara H; Mizukami T; Moriwaki T; Ohtsubo K; Komoda M; Mitani S; Nagashima F; Kato K; Yamada T; Hasegawa H; Yamazaki K; Yoshino T; Hyodo I
JCO Precis Oncol; 2022 Aug; 6():e2200135. PubMed ID: 35952320
[TBL] [Abstract][Full Text] [Related]
2.
Zhang L; Hamdani O; Gjoerup O; Cho-Phan C; Snider J; Castellanos E; Nimeiri H; Frampton G; Venstrom JM; Oxnard G; Klempner SJ; Schrock AB
JCO Precis Oncol; 2022 Jan; 6():e2100330. PubMed ID: 35050711
[TBL] [Abstract][Full Text] [Related]
3. Real-world association of HER2/
Stein SM; Snider J; Ali SM; Miksad RA; Alexander BM; Castellanos E; Schrock AB; Madison R; Swaminathan A; Venstrom JM; McCusker M
Future Oncol; 2021 Nov; 17(31):4101-4114. PubMed ID: 34463133
[TBL] [Abstract][Full Text] [Related]
4. Impact of Genomic Alterations on Efficacy of Trastuzumab Deruxtecan Against Human Epidermal Growth Factor Receptor-2-Positive Advanced Gastric Cancer.
Yamaguchi K; Ito M; Isobe T; Koreishi S; Taguchi R; Uehara K; Ueno S; Imajima T; Kitazono T; Tsuchihashi K; Ohmura H; Yoshihiro T; Tanoue K; Nishiyori S; Iwama E; Maeda T; Akashi K; Baba E
JCO Precis Oncol; 2024 May; 8():e2300681. PubMed ID: 38748981
[TBL] [Abstract][Full Text] [Related]
5. Genomic Profiling of HER2-Positive Gastric Cancer: PI3K/Akt/mTOR Pathway as Predictor of Outcomes in HER2-Positive Advanced Gastric Cancer Treated with Trastuzumab.
Díaz-Serrano A; Angulo B; Dominguez C; Pazo-Cid R; Salud A; Jiménez-Fonseca P; Leon A; Galan MC; Alsina M; Rivera F; Plaza JC; Paz-Ares L; Lopez-Rios F; Gómez-Martín C
Oncologist; 2018 Sep; 23(9):1092-1102. PubMed ID: 29700210
[TBL] [Abstract][Full Text] [Related]
6.
Sanchez-Vega F; Hechtman JF; Castel P; Ku GY; Tuvy Y; Won H; Fong CJ; Bouvier N; Nanjangud GJ; Soong J; Vakiani E; Schattner M; Kelsen DP; Lefkowitz RA; Brown K; Lacouture ME; Capanu M; Mattar M; Qeriqi B; Cecchi F; Tian Y; Hembrough T; Nagy RJ; Lanman RB; Larson SM; Pandit-Taskar N; Schöder H; Iacobuzio-Donahue CA; Ilson DH; Weber WA; Berger MF; de Stanchina E; Taylor BS; Lewis JS; Solit DB; Carrasquillo JA; Scaltriti M; Schultz N; Janjigian YY
Cancer Discov; 2019 Feb; 9(2):199-209. PubMed ID: 30463996
[TBL] [Abstract][Full Text] [Related]
7. Predictive Roles of HER2 Gene Amplification and Neutrophil-to-Lymphocyte Ratio on Survival in HER2-Positive Advanced Gastric Cancer Treated With Trastuzumab-Based Chemotherapy.
Park JH; Yeo JH; Kim YS; Park I; Ahn HK; Shin DB; Lee WK; Yang JY; Kim HS; Sym SJ
Am J Clin Oncol; 2021 Jun; 44(6):232-238. PubMed ID: 33710139
[TBL] [Abstract][Full Text] [Related]
8. High-level ERBB2 gene amplification is associated with a particularly short time-to-metastasis, but results in a high rate of complete response once trastuzumab-based therapy is offered in the metastatic setting.
Fuchs EM; Köstler WJ; Horvat R; Hudelist G; Kubista E; Attems J; Zielinski CC; Singer CF
Int J Cancer; 2014 Jul; 135(1):224-31. PubMed ID: 24311197
[TBL] [Abstract][Full Text] [Related]
9. RAS/RAF Comutation and ERBB2 Copy Number Modulates HER2 Heterogeneity and Responsiveness to HER2-directed Therapy in Colorectal Cancer.
Singh H; Sahgal P; Kapner K; Corsello SM; Gupta H; Gujrathi R; Li YY; Cherniack AD; El Alam R; Kerfoot J; Andrews E; Lee A; Nambiar C; Hannigan AM; Remland J; Brais L; Leahy ME; Rubinson DA; Schlechter BL; Meyerson M; Kuang Y; Paweletz CP; Lee JK; Quintanilha JCF; Aguirre AJ; Perez KJ; Huffman BM; Rossi H; Abrams TA; Kabraji S; Trusolino L; Bertotti A; Sicinska ET; Parikh AR; Wolpin BM; Schrock AB; Giannakis M; Ng K; Meyerhardt JA; Hornick JL; Sethi NS; Cleary JM
Clin Cancer Res; 2024 Apr; 30(8):1669-1684. PubMed ID: 38345769
[TBL] [Abstract][Full Text] [Related]
10. Depth of response predicts the clinical outcome of advanced HER2-positive gastric cancer to trastuzumab-based first-line chemotherapy.
Kadowaki S; Masuishi T; Eto T; Narita Y; Taniguchi H; Ura T; Ando M; Tajika M; Niwa Y; Yatabe Y; Muro K
Cancer Chemother Pharmacol; 2017 Oct; 80(4):807-813. PubMed ID: 28821938
[TBL] [Abstract][Full Text] [Related]
11. Oncogenic alterations in ERBB2/HER2 represent potential therapeutic targets across tumors from diverse anatomic sites of origin.
Chmielecki J; Ross JS; Wang K; Frampton GM; Palmer GA; Ali SM; Palma N; Morosini D; Miller VA; Yelensky R; Lipson D; Stephens PJ
Oncologist; 2015 Jan; 20(1):7-12. PubMed ID: 25480824
[TBL] [Abstract][Full Text] [Related]
12. Neratinib is effective in breast tumors bearing both amplification and mutation of ERBB2 (HER2).
Cocco E; Javier Carmona F; Razavi P; Won HH; Cai Y; Rossi V; Chan C; Cownie J; Soong J; Toska E; Shifman SG; Sarotto I; Savas P; Wick MJ; Papadopoulos KP; Moriarty A; Cutler RE; Avogadri-Connors F; Lalani AS; Bryce RP; Chandarlapaty S; Hyman DM; Solit DB; Boni V; Loi S; Baselga J; Berger MF; Montemurro F; Scaltriti M
Sci Signal; 2018 Oct; 11(551):. PubMed ID: 30301790
[TBL] [Abstract][Full Text] [Related]
13. HER2-positive patients receiving trastuzumab treatment have a comparable prognosis with HER2-negative advanced gastric cancer patients: a prospective cohort observation.
Qiu MZ; Li Q; Wang ZQ; Liu TS; Liu Q; Wei XL; Jin Y; Wang DS; Ren C; Bai L; Zhang DS; Wang FH; Li YH; Xu RH
Int J Cancer; 2014 May; 134(10):2468-77. PubMed ID: 24155030
[TBL] [Abstract][Full Text] [Related]
14. HER2 copy number as predictor of disease-free survival in HER2-positive resectable gastric adenocarcinoma.
Liu Z; Shi M; Li X; Song S; Liu N; Du H; Ye J; Li H; Zhang Z; Zhang L
J Cancer Res Clin Oncol; 2021 May; 147(5):1315-1324. PubMed ID: 33543328
[TBL] [Abstract][Full Text] [Related]
15. The impact of concomitant genomic alterations on treatment outcome for trastuzumab therapy in HER2-positive gastric cancer.
Lee JY; Hong M; Kim ST; Park SH; Kang WK; Kim KM; Lee J
Sci Rep; 2015 Mar; 5():9289. PubMed ID: 25786580
[TBL] [Abstract][Full Text] [Related]
16. HER2 Copy Number and Resistance Mechanisms in Patients with HER2-positive Advanced Gastric Cancer Receiving Initial Trastuzumab-based Therapy in JACOB Trial.
Pietrantonio F; Manca P; Bellomo SE; Corso S; Raimondi A; Berrino E; Morano F; Migliore C; Niger M; Castagnoli L; Pupa SM; Marchiò C; Di Bartolomeo M; Restuccia E; Lambertini C; Tabernero J; Giordano S
Clin Cancer Res; 2023 Feb; 29(3):571-580. PubMed ID: 36413222
[TBL] [Abstract][Full Text] [Related]
17. A prognostic scoring system for conversion surgery after trastuzumab-based chemotherapy for human epidermal growth factor receptor 2-positive advanced gastric cancer.
Arigami T; Matsushita D; Okubo K; Shimonosono M; Sasaki K; Tsuruda Y; Kita Y; Tanabe K; Mori S; Yanagita S; Uenosono Y; Nakajo A; Kurahara H; Ohtsuka T
Surg Today; 2022 Dec; 52(12):1721-1730. PubMed ID: 35543754
[TBL] [Abstract][Full Text] [Related]
18. Optimal Patient Selection for Trastuzumab Treatment in HER2-Positive Advanced Gastric Cancer.
Ock CY; Lee KW; Kim JW; Kim JS; Kim TY; Lee KH; Han SW; Im SA; Kim TY; Kim WH; Bang YJ; Oh DY
Clin Cancer Res; 2015 Jun; 21(11):2520-9. PubMed ID: 25712681
[TBL] [Abstract][Full Text] [Related]
19. HER2 copy number of circulating tumour DNA functions as a biomarker to predict and monitor trastuzumab efficacy in advanced gastric cancer.
Wang H; Li B; Liu Z; Gong J; Shao L; Ren J; Niu Y; Bo S; Li Z; Lai Y; Lu S; Gao J; Shen L
Eur J Cancer; 2018 Jan; 88():92-100. PubMed ID: 29207318
[TBL] [Abstract][Full Text] [Related]
20. Digital PCR quantification of ultrahigh ERBB2 copy number identifies poor breast cancer survival after trastuzumab.
Meng P; Dalal H; Chen Y; Brueffer C; Gladchuk S; Alcaide M; Ehinger A; Saal LH
NPJ Breast Cancer; 2024 Feb; 10(1):14. PubMed ID: 38374091
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
